Astron Corp Ltd

Rakovina Therapeutics and Saudi-based NanoPalm have signed a non-binding Letter of Intent to form a joint venture focused on developing AI-discovered oncology therapeutics using advanced lipid nanoparticle delivery systems.

Independent researchers found that biliary tract cancer cell lines demonstrated sensitivity to plogosertib, a PLK1 inhibitor, both as monotherapy and in combination treatments.

AptarGroup has developed a breakthrough dual-active material science technology that simultaneously controls moisture and oxygen to protect sensitive pharmaceutical formulations.

Aptar's clinical study aims to validate its SmartTrack™ platform as an in-vitro-in-silico alternative to comparative clinical endpoint studies for generic inhaled drug products, potentially eliminating a major regulatory hurdle.

Rakovina Therapeutics presented preclinical data at AACR 2025 showcasing AI-discovered PARP1 inhibitors with improved metabolic stability and potential CNS penetration for brain malignancies.

• Repare Therapeutics' phase I trial of lunresertib and camonsertib in gynecological cancers with specific biomarkers showed mixed results, impacting stock prices. • Beigene secured a global licensing agreement with CSPC for SYH-2039, a phase I MAT2A inhibitor targeting solid tumors, for up to $1.5 billion. • A new study identifies inceptor as a novel insulin receptor that degrades insulin, potentially opening new avenues for diabetes therapeutics. • GC Biopharma will acquire Abo Holdings for $96.28 million to enhance its U.S. plasma business and accelerate the entry of Alyglo (IVIG-SN 10%).

• Repare Therapeutics' MYTHIC Phase 1 trial shows Lunre+Camo achieved a 25.9% ORR in endometrial cancer and 37.5% in platinum-resistant ovarian cancer. • Nearly half of gynecologic cancer patients maintained progression-free survival at 24 weeks, suggesting a potential improvement over current standards of care. • Repare plans to initiate a Phase 3 trial for Lunre+Camo in endometrial cancer in the second half of 2025, pending regulatory clearance. • The combination therapy demonstrated a favorable tolerability profile, with anemia being the most common Grade 3 adverse event.

• Aprea Therapeutics initiates twice-daily dosing of ATRN-119 at 550mg in the ABOYA-119 Phase 1/2a trial to maintain optimal therapeutic levels. • The trial evaluates ATRN-119 as a monotherapy for advanced solid tumors with DNA damage response gene mutations, potentially enhancing efficacy. • Phase 1 readout is anticipated in the second half of 2025, with dose escalation continuing independently for both once-daily and twice-daily schedules. • ATRN-119 is the first macrocyclic ATR inhibitor in clinical trials and the only one tested as a monotherapy on a continuous twice-daily schedule.

• Repare Therapeutics will present Phase 1 MYTHIC trial data for lunresertib combined with camonsertib in platinum-resistant ovarian and endometrial cancers. • The trial focuses on patients with CCNE1 amplification or FBXW7 or PPP2R1A mutations, evaluating the combination at the recommended Phase 2 dose. • The presentation will occur during a live webcast on December 12, 2024, featuring Repare's management and Dr. Brian Slomovitz from Mount Sinai Medical Center. • The MYTHIC trial assesses the safety and efficacy of this novel therapeutic approach in addressing genomic instability in advanced cancers.

• Repare Therapeutics and the National Cancer Institute (NCI) have entered a Cooperative Research and Development Agreement (CRADA) to further develop camonsertib. • The collaboration aims to explore camonsertib's potential as an anticancer agent, including combination studies with radiation therapy and biomarker identification. • Camonsertib has shown promising anti-tumor activity in clinical trials, particularly in ATM-mutated non-small cell lung cancer and ATM-altered tumors. • The partnership seeks to leverage CTEP's resources to accelerate camonsertib's clinical development and broaden its application across cancer types.